GS
REGN icon

George Soros’s Regeneron Pharmaceuticals REGN Stock Holding History

George Soros’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,000
Closed -$14.4M – 216
2024
Q1 		$14.4M Sell
15,000
-2,500
-14% -$2.38M 0.24% 101
2023
Q4 		$15.4M Buy
+17,500
New +$14.4M 0.2% 115
2016
Q4 		– Sell
-1,381
Closed -$555K – 280
2016
Q3 		$555K Buy
+1,381
New +$554K 0.01% 162

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

George Soros's REGN Position: Q2 2024 in Review

George Soros sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 15,000 shares — an estimated $14.4M sold.

George Soros first reported a position in REGN in Q3 2016 and held it in 3 quarters. The position peaked at $15.4M in Q4 2023. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • George Soros reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • George Soros sold 15,000 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $14.4M.
  • George Soros first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • George Soros's Regeneron Pharmaceuticals position peaked at $15.4M in Q4 2023.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Soros Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.